🟢 Arcturus Therapeutics is trading 5% up today as investors await late-September ARCT-810 Phase II readout

Arcturus Therapeutics is trading 5.02% up at $15.47, with investor attention focused on the expected late-September ARCT-810 Phase II readout and regulatory update despite modest declines in major U.S. indexes.

• No new company-specific announcement on September 14, 2026, clearly explains the move.
• Management is scheduled to present at the H.C. Wainwright conference on September 15.